A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab

Published:2004-09 Issue:5 Volume:15 Page:280-294
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Scheinfeld N

Publisher

Informa UK Limited

Subject

Dermatology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10256018808623883

Reference120 articles.

1. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment

2. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives

3. Lymphoma Rates Are Low but Increased in Patients With Psoriasis

4. Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration

5. Comorbid conditions in patients with rheumatic diseases: an update

Cited by 236 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis;Expert Opinion on Drug Safety;2024-08-17

2. Ethanolic extract of Arctium lappa leaves alleviates cerebral ischemia reperfusion-induced inflammatory injury via HDAC9-mediated NF-κB pathway;Phytomedicine;2024-07

3. Molecular Pathogenesis of Ischemic and Hemorrhagic Strokes: Background and Therapeutic Approaches;International Journal of Molecular Sciences;2024-06-07

4. Effect of adalimumab as an anti-inflammatory agent on gene expression of retinal pigment epithelial cells;Biomedicine & Pharmacotherapy;2024-05

5. Anti–Tumor Necrosis Factor Therapy and Risk of Kidney Function Decline and Mortality in Inflammatory Bowel Disease;JAMA Network Open;2024-04-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3